Liver Illness and Psychiatric Patients

Area of Science:

• Psychiatry
• Hepatology
• Clinical Pharmacology

Background:

• Patients with psychiatric disorders exhibit increased comorbidity with somatic illnesses, particularly liver diseases.
• Established links exist between psychiatric conditions and various hepatitis types (viral, alcoholic), especially in substance abusers.
• Metabolic syndrome, steatosis, and non-alcoholic steato-hepatitis (NASH) are prevalent in individuals with chronic psychiatric disorders undergoing psychotropic treatment.

Purpose of the Study:

• To highlight the increased prevalence of liver diseases in psychiatric patients.
• To underscore the association between psychotropic medications and drug-induced liver injury (DILI).
• To emphasize the need for screening and careful management of liver health in this population.

Main Methods:

• Review of existing literature on psychiatric disorders and liver disease.
• Analysis of the impact of psychotropic medications on liver function.
• Evaluation of screening protocols for liver conditions in psychiatric patients.

Main Results:

• Psychiatric patients are disproportionately affected by liver conditions like hepatitis and NASH.
• Specific psychiatric medications (neuroleptics, mood stabilizers, antidepressants) are linked to drug-induced liver injury (DILI).
• Advanced liver disease may contraindicate certain psychiatric treatments, and psychiatric status can impact liver transplant eligibility.

Conclusions:

• Close monitoring for liver disease is crucial in psychiatric patients, especially those on psychotropic drugs.
• Screening for metabolic syndrome and NASH should be routine.
• Careful consideration of medication interactions and patient history is vital for managing liver health in psychiatric populations.